Turning Point Therapeutics

Turning Point Therapeutics is a clinical-stage biopharmaceutical company designing and developing novel small molecule, targeted oncology therapies. The company develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-na?ve and TKI-pretreated patients. The company's lead drug candidate repotrectinib (TPX-0005) is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+ or ALK+ advanced solid tumors. The company's principal operations are in the United States.
  • TickerTPTX
  • ISINUS90041T1088
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

ValuEngine Rating and Forecast Report for TPTX

ValuEngine Rating and Forecast Report for TPTX

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Matthew Barcus
  • Robert Driscoll

AACR II 2020 Abstract Roundup for Covered Companies

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Round Trip Back To Resistance Our base case continues to be for near-term consolidation while the market determines the implications of states' reopening (i.e., the “wait-and-see” phase). Until this consolidation period resolves below support or above resistance we are maintaining a relatively neutral stance considering the wide range of outcomes. Below we highlight new developments which remain generally positive. Still, many major indexes are testing logical resistance and until we see breakouts it is hard to get too bullish. · Short-Term Levels. The S&P 500 is at the upper-end of ...

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Matthew Barcus
  • Robert Driscoll

AACR II 2020 Abstract Roundup for Covered Companies

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Round Trip Back To Resistance Our base case continues to be for near-term consolidation while the market determines the implications of states' reopening (i.e., the “wait-and-see” phase). Until this consolidation period resolves below support or above resistance we are maintaining a relatively neutral stance considering the wide range of outcomes. Below we highlight new developments which remain generally positive. Still, many major indexes are testing logical resistance and until we see breakouts it is hard to get too bullish. · Short-Term Levels. The S&P 500 is at the upper-end of ...

David Nierengarten ...
  • Jeffrey La Rosa
  • Matthew Barcus

New Repo Data; Turning Up the PT ahead of TRIDENT-1 Update in Q3:20

Wedbush Research

Wedbush Morning Call - May 11 2020 6:54AM

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kambiz Yazdi
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

ValuEngine Rating and Forecast Report for TPTX

ValuEngine Rating and Forecast Report for TPTX

ValuEngine Rating and Forecast Report for TPTX

ValuEngine Rating and Forecast Report for TPTX

ValuEngine Rating and Forecast Report for TPTX

ValuEngine Rating and Forecast Report for TPTX

ValuEngine Rating and Forecast Report for TPTX

ValuEngine Rating and Forecast Report for TPTX

ValuEngine Rating and Forecast Report for TPTX

ValuEngine Rating and Forecast Report for TPTX

ResearchPool Subscriptions

Get the most out of your insights

Get in touch